Federal governments Bombardier Inc study cost taxpayers 500000

MONTREAL — Canadian taxpayers spent almost $500,000 on a study of Bombardier that was launched months before the Montreal company asked the federal government for US$1 billion for its CSeries commercial aircraft, according to documents obtained by The Canadian Press.Industry Canada agreed to pay $499,930 to Deloitte Inc. to prepare a financial and market assessment of Bombardier, said a revised contract obtained through an access-to-information request.That’s higher than the original contract for $464,430 before Deloitte’s deadline to compile the report by Dec. 4 was extended to March 31.Details about the objective of the report were redacted. The government declined to provide the final report, citing clauses under the Access to Information Act that prevent it from releasing information that could harm Bombardier’s competitive position.Air Canada will firm up Bombardier Inc CSeries order within ‘weeks,’ CEO saysBombardier Inc shakes up rail division’s management in EuropeThe study was ordered in August by the previous Conservative government.The Liberal government later reportedly hired Morgan Stanley to help advise it on the funding request made in December by Bombardier. Details about that contract weren’t immediately available.A spokesman for Economic Development Minister Navdeep Bains said the government hasn’t made a final decision on Bombardier’s request.Bombardier is working with the Quebec government to finalize an agreement by June 30 on its commitment to invest $1 billion in the CSeries.Quebec wants the CSeries venture to be spun off into a separate entity, with Ottawa taking a one-third stake. That would take the troubled jet program off the company’s books and boost its short-term financial results.The first of the CSeries jets is entering service in a few months after years of delays. Bombardier has received commitments for 678 planes, including 243 firm orders. It currently controls 50.5 per cent of the CSeries, while Quebec has a 49.5 per cent stake.Under Quebec’s proposal, if Ottawa matches the province’s contribution, both governments would each own one-third stakes in the CSeries, with Bombardier left with the remainder.The Canadian Press read more

NHS agrees to fund drug for children with incurable Batten disease after High

“We are in talks with Nice as to what happens next. We thank you to everyone from the bottom of our hearts.”Prince Harry met Ollie on a private visit to Great Ormond Street Hospital in London in 2017. Samantha Barber, chief executive of the Batten Disease Family Association, said: “Today’s announcement will be a huge relief to all those families affected who have fought night and day for this outcome.”Brineura offers real hope for these children and the priority now must be to ensure all those who need it get access as soon as possible.”While we recognise the efforts made on both sides to reach this agreement, the reality is that it has taken nearly two years to get to this point.”The human cost of this delay and the anguish caused cannot be underestimated and we hope that efforts will be made to help others avoid this heartache in the future.”For now, we are absolutely delighted with this decision, which is a critical step forward in improving the lives of children affected by this devastating condition.”Simon Stevens, chief executive of NHS England, said: “This is another concrete step towards ensuring NHS patients with rare conditions get access to important new treatments. Want the best of The Telegraph direct to your email and WhatsApp? Sign up to our free twice-daily  Front Page newsletter and new  audio briefings. Prince Harry Great Ormond Street Hospital Visit It usually starts in childhood, with an estimated 25 to 40 children living with the condition in England.NHS England said cerliponase alfa would be offered to sufferers not currently receiving treatment by Christmas at the latest.In February, the parents of a brother and sister with Batten disease said they were “devastated” their treatment would not be funded by the NHS.Ollie and Amelia Carroll, aged eight and six, from Poynton, Cheshire, have the condition and their parents were given permission to seek a judicial review.On Wednesday their parents said: “We are in utter shock right now… we sit in tears with the news that the National Institute for Health and Care Excellence have now recommended the only treatment for Batten disease to children in England. The NHS has agreed to fund a drug for children with a rare degenerative disease – weeks before families were due to go to court.Two sets of parents of children with Batten disease had been prepared to take their fight for the drug cerliponase alfa (Brineura) to the High Court.NHS England announced on Wednesday that an agreement on price had been struck with the drug’s manufacturer Biomarin.The National Institute for Health and Care Excellence (Nice) had previously said it could not be certain the drug was value for money.Batten disease is an incurable illness which affects the nervous system, causing seizures, visual impairment, mobility loss and early death. Prince Harry with Ollie Carroll who suffers from Batten diseaseCredit:Family Handout/PA “Over recent months there’ve been a series of successful deals as NHS England works closely with the life sciences sector to make life-changing new drugs available for haemophilia, MS, rare cancers and other conditions.”Coming after extended negotiation, the new deal reached today is a reminder that in order to succeed, companies must be flexible and realistic, because the NHS in England cannot and will not simply write blank cheques at taxpayers’ expense.”Health Secretary Matt Hancock said: “I’m absolutely delighted this new treatment will be funded by the NHS, giving families dealing with the devastating impact of Batten disease renewed hope for a better quality of life for their child. Through our Long Term Plan, we want all patients to have access to the most pioneering, value for money medicines – this is a great example of how we can work with industry to get treatments to patients as quickly as possible.” read more